DUBLIN–(BUSINESS WIRE)–The “GABA Receptor Agonists – Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering.
This “GABA Receptor Agonists – Pipeline Insight, 2022” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in GABA Receptor Agonists pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The assessment part of the report embraces, in depth GABA Receptor Agonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, GABA Receptor Agonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence GABA Receptor Agonists R&D. The therapies under development are focused on novel approaches to treat/improve GABA Receptor Agonists.
GABA Receptor Agonists Emerging Drugs Chapters
This segment of the GABA Receptor Agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
GABA Receptor Agonists Emerging Drugs
Ganaxolone: Marinus Pharmaceuticals
Ganaxolone, a positive allosteric modulator of GABAA receptors, is an investigational product being developed in intravenous and oral formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.
Ganaxolone exhibits anti-seizure and anti-anxiety activity via its effects on synaptic and extrasynaptic GABAA receptors. In August 2021, Marinus Pharmaceuticals announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of its lead product candidate ganaxolone, to treat seizures associated with CDKL5 deficiency disorder (CDD), a rare, genetic epilepsy.
EMB-001: Embera NeuroTherapeutics
EMB-001 is a patented combination product comprised of two FDA-approved medications, the cortisol synthesis inhibitor metyrapone and the benzodiazepine oxazepam. The innovation is based on insights into the physiological responses to stress in addiction. It is being developed by Embera NeuroTherapeutics and is currently in Phase II/III stage of development for the treatment of Smoking Cessation and Tobacco Use Disorder.
GABA Receptor Agonists: Therapeutic Assessment
This segment of the report provides insights about the different GABA Receptor Agonists drugs segregated based on following parameters that define the scope of the report.
Major Players in GABA Receptor Agonists
There are approx. 25+ key companies which are developing the therapies for GABA Receptor Agonists. The companies which have their GABA Receptor Agonists drug candidates in the most advanced stage, i.e. Pre-registration include, Marinus Pharmaceuticals.
Key Questions
- How many companies are developing GABA Receptor Agonists drugs?
- How many GABA Receptor Agonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of GABA Receptor Agonists?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the GABA Receptor Agonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for GABA Receptor Agonists and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Marinus Pharmaceuticals
- Embera NeuroTherapeutics
- XWPharma
- Xeris Pharmaceuticals
- Haisco Pharmaceutical Group
- Addex Therapeutics
Key Products
- Ganaxolone
- EMB-001
- XW10172
- XP-0863
- HSK-3486
Research Programme:
- Allosteric modulators
Key Topics Covered:
Introduction
Executive Summary
GABA Receptor Agonists: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Late Stage Products (Pre-registration)
- Comparative Analysis
Ganaxolone: Marinus Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II/III)
- Comparative Analysis
EMB-001: Embera NeuroTherapeutics
- Product Description
- Research and Development
- Product Development Activities
Early stage products (Phase I)
- Comparative Analysis
XP-0863: Xeris Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Preclinical stage products
- Comparative Analysis
Research programme: allosteric modulators: Addex Therapeutics
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
GABA Receptor Agonists Key Companies
GABA Receptor Agonists Key Products
GABA Receptor Agonists- Unmet Needs
GABA Receptor Agonists- Market Drivers and Barriers
GABA Receptor Agonists- Future Perspectives and Conclusion
GABA Receptor Agonists Analyst Views
GABA Receptor Agonists Key Companies
Appendix
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/i4e9jv
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900